ACC announces late-breaking clinical trials for annual scientific session

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
 - conference speaker audience

The American College of Cardiology (ACC) announced the late-breaking clinical trials sessions for its 65 th annual scientific session. The conference is taking place from April 2 to 4 at the McCormick Place convention center in Chicago.

Here are the late-breaking trials (all times are Central time):

April 2 in North Hall B1

9:05 a.m. – “Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate Risk Patients with Aortic Stenosis: Final Results from the Randomized Placement of Aortic Transcatheter Valves 2 Study.” – lead researcher Martin B. Leon, MD

9:27 a.m. – “Blood Pressure Lowering in People at Moderate Risk. The HOPE-3 Trial.” – lead researcher Eva M. Lonn, MD

9:37 a.m. – “Effects of Combined Lipid and BP-Lowering on Cardiovascular Disease in a Moderate Risk Global Primary Prevention Population.” – lead researcher Salim Yusuf, MD

April 3 in North Hall B1

8:00 a.m. – “Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Events: Results of the ACCELERATE trial.” – lead researcher Stephen J. Nicholls, MD

8:15 a.m. – “Comparison of PCSK9 Inhibitor Evolocumab Versus Ezetimibe in Statin-intolerant Patients: The Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects 3 (GAUSS-3) Trial.” – lead researcher Steven E. Nissen, MD

8:30 a.m. – “Low-density Lipoprotein Cholesterol, Familial Hypercholesterolemia Mutation Status and Risk for Coronary Artery Disease.” – lead researcher Amit V. Khera, MD

8:45 a.m. – “Reproducible Impact of a Global Mobile Health (mHealth) Mass-Participation Physical Activity Intervention on Step Count, Sitting Behavior and Weight: the Stepathlon Cardiovascular Health Study.” – lead researcher Anand Ganesan, MD

9:00 a.m. – “Involving Patients with Low Risk Chest Pain in Discharge Decisions: A Multicenter Trial.” – lead researcher Erik P. Hess, MD

10:45 a.m. – “The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: DEFERred stent implantation in connection with primary PCI.” – lead researcher Henning Kelbaek, MD

11:00 a.m. – “The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: iPOSTconditioning during primary PCI.” – lead researcher Thomas Engstrom, MD

11:15 a.m. – “Effect Of Early Administration Of Intravenous Beta Blockers In Patients With ST-elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. The Early-BAMI trial.” – lead researcher Vincent Roolvink, MD

11:30 a.m. – “Sapien 3 Transcatheter Aortic Valve Replacement versus Surgery in Intermediate-Risk Patients with Severe Aortic Stenosis: A Propensity-Matched Comparison of One-Year Outcomes.” – lead researcher Vinod H. Thourani, MD

11:45 a.m. – “Relationship Between Procedure Volume and Outcome for Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: Insights from the STS/ACC TVT Registry.” – lead researcher John D. Carroll, MD

April 4 in North Hall B1

8:00 a.m. – “Antiarrhythmic Drugs for Shock-Refractory Out-of-Hospital Cardiac Arrest: The Resuscitation Outcomes Consortium Amiodarone, Lidocaine or Placebo Study.” – lead researcher Peter J. Kudenchuk, MD

8:15 a.m. – “Largest Randomized Trial Demonstrates an Effective Ablation of Atrial Fibrillation: the FIRE AND ICE Trial (NCT01490814).” – lead researcher Karl-Heinz Kuck, MD

8:30 a.m. – “A Randomized Trial of Rate Control Versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery.” – lead researcher A. Marc Gillinov, MD

8:45 a.m. – “The Losmapimod To Inhibit P38 MAP Kinase As A Therapeutic Target And Modify Outcomes After An Acute Coronary Syndrome (LATITUDE-TIMI 60) Trial: Primary Results Of Part A.” – lead researcher Michelle L. O’Donoghue, MD

9:00 a.m. – “CMX-2043 for Prevention of Contrast Induced Acute Kidney Injury: The Primary Results of the CARIN Trial.” – lead researcher Deepak L. Bhatt, MD

10:45 a.m. – “Direct Renin-inhibition With Aliskiren Alone And In Combination With Enalapril, Compared With Enalapril, In Heart Failure (the ATMOSPHERE Trial).” – lead researcher John J.V. McMurray, MD

11:00 a.m. – “Effect of Ularitide on Short- and Long-Term Clinical Course of Patients with Acutely Decompensated Heart Failure: Primary Results of the TRUE-AHF Trial.” – lead researcher Milton Packer, MD

11:15 a.m. – “The Final Results of the IxCell-DCM Trial: Transendocardial Injection of Ixmyelocel-T in Patients with Ischemic Dilated Cardiomyopathy.”